Harrow Health, Inc. 11.875% Senior Notes due 2027
Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Stock Competitors & Peer Comparison
See (HROWM) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HROWM | $26.03 | -0.08% | 1.3B | N/A | N/A | N/A |
| ONC | $298.92 | -0.62% | 31.9B | 121.01 | $2.47 | N/A |
| WBA | $11.98 | +0.50% | 10.4B | -1.64 | -$7.29 | +2.09% |
| DMRA | $25.50 | +3.03% | 1.5B | -6.41 | -$3.98 | N/A |
| HROWL | $25.61 | +0.19% | 1.4B | N/A | N/A | N/A |
| ATAI | $4.33 | -6.48% | 816.7M | -1.49 | -$2.91 | N/A |
| CGEM | $13.25 | +0.19% | 802M | -3.94 | -$3.36 | N/A |
| HITI | $2.56 | +3.44% | 224.6M | -6.08 | -$0.42 | N/A |
| LFMD | $4.56 | -1.72% | 218.8M | -15.20 | -$0.30 | N/A |
| LFMDP | $23.75 | -0.71% | 161.9M | -10.53 | -$2.26 | N/A |
Stock Comparison
HROWM vs ONC Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ONC has a market cap of 31.9B. Regarding current trading prices, HROWM is priced at $26.03, while ONC trades at $298.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ONC's P/E ratio is 121.01. In terms of profitability, HROWM's ROE is -0.10%, compared to ONC's ROE of +0.07%. Regarding short-term risk, HROWM is less volatile compared to ONC. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check ONC's competition here
HROWM vs WBA Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, HROWM is priced at $26.03, while WBA trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas WBA's P/E ratio is -1.64. In terms of profitability, HROWM's ROE is -0.10%, compared to WBA's ROE of -0.39%. Regarding short-term risk, HROWM is more volatile compared to WBA. This indicates potentially higher risk in terms of short-term price fluctuations for HROWM.Check WBA's competition here
HROWM vs DMRA Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, DMRA has a market cap of 1.5B. Regarding current trading prices, HROWM is priced at $26.03, while DMRA trades at $25.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas DMRA's P/E ratio is -6.41. In terms of profitability, HROWM's ROE is -0.10%, compared to DMRA's ROE of -3.12%. Regarding short-term risk, HROWM is less volatile compared to DMRA. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check DMRA's competition here
HROWM vs HROWL Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, HROWM is priced at $26.03, while HROWL trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas HROWL's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.10%, compared to HROWL's ROE of -0.10%. Regarding short-term risk, HROWM is less volatile compared to HROWL. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check HROWL's competition here
HROWM vs ATAI Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ATAI has a market cap of 816.7M. Regarding current trading prices, HROWM is priced at $26.03, while ATAI trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ATAI's P/E ratio is -1.49. In terms of profitability, HROWM's ROE is -0.10%, compared to ATAI's ROE of -3.90%. Regarding short-term risk, HROWM is less volatile compared to ATAI. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check ATAI's competition here
HROWM vs CGEM Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CGEM has a market cap of 802M. Regarding current trading prices, HROWM is priced at $26.03, while CGEM trades at $13.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CGEM's P/E ratio is -3.94. In terms of profitability, HROWM's ROE is -0.10%, compared to CGEM's ROE of -0.46%. Regarding short-term risk, HROWM is less volatile compared to CGEM. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check CGEM's competition here
HROWM vs HITI Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, HITI has a market cap of 224.6M. Regarding current trading prices, HROWM is priced at $26.03, while HITI trades at $2.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas HITI's P/E ratio is -6.08. In terms of profitability, HROWM's ROE is -0.10%, compared to HITI's ROE of -0.41%. Regarding short-term risk, HROWM is less volatile compared to HITI. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check HITI's competition here
HROWM vs LFMD Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LFMD has a market cap of 218.8M. Regarding current trading prices, HROWM is priced at $26.03, while LFMD trades at $4.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LFMD's P/E ratio is -15.20. In terms of profitability, HROWM's ROE is -0.10%, compared to LFMD's ROE of -1.18%. Regarding short-term risk, HROWM is less volatile compared to LFMD. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check LFMD's competition here
HROWM vs LFMDP Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LFMDP has a market cap of 161.9M. Regarding current trading prices, HROWM is priced at $26.03, while LFMDP trades at $23.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LFMDP's P/E ratio is -10.53. In terms of profitability, HROWM's ROE is -0.10%, compared to LFMDP's ROE of -1.18%. Regarding short-term risk, HROWM is less volatile compared to LFMDP. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check LFMDP's competition here
HROWM vs LFLY Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LFLY has a market cap of 114.9M. Regarding current trading prices, HROWM is priced at $26.03, while LFLY trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LFLY's P/E ratio is -0.04. In terms of profitability, HROWM's ROE is -0.10%, compared to LFLY's ROE of +0.17%. Regarding short-term risk, HROWM is less volatile compared to LFLY. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check LFLY's competition here
HROWM vs YI Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, YI has a market cap of 58.3M. Regarding current trading prices, HROWM is priced at $26.03, while YI trades at $6.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas YI's P/E ratio is -0.30. In terms of profitability, HROWM's ROE is -0.10%, compared to YI's ROE of +0.08%. Regarding short-term risk, HROWM is less volatile compared to YI. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check YI's competition here
HROWM vs PETS Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, PETS has a market cap of 49.2M. Regarding current trading prices, HROWM is priced at $26.03, while PETS trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas PETS's P/E ratio is -0.74. In terms of profitability, HROWM's ROE is -0.10%, compared to PETS's ROE of -1.22%. Regarding short-term risk, HROWM is less volatile compared to PETS. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check PETS's competition here
HROWM vs RNTX Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, RNTX has a market cap of 42.1M. Regarding current trading prices, HROWM is priced at $26.03, while RNTX trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas RNTX's P/E ratio is -0.77. In terms of profitability, HROWM's ROE is -0.10%, compared to RNTX's ROE of -2.81%. Regarding short-term risk, HROWM is less volatile compared to RNTX. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check RNTX's competition here
HROWM vs RAD Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, HROWM is priced at $26.03, while RAD trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas RAD's P/E ratio is -0.05. In terms of profitability, HROWM's ROE is -0.10%, compared to RAD's ROE of +2.76%. Regarding short-term risk, HROWM is less volatile compared to RAD. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check RAD's competition here
HROWM vs SDEV Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SDEV has a market cap of 35M. Regarding current trading prices, HROWM is priced at $26.03, while SDEV trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SDEV's P/E ratio is -0.23. In terms of profitability, HROWM's ROE is -0.10%, compared to SDEV's ROE of +12.37%. Regarding short-term risk, HROWM is less volatile compared to SDEV. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check SDEV's competition here
HROWM vs POM Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, POM has a market cap of 34.2M. Regarding current trading prices, HROWM is priced at $26.03, while POM trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas POM's P/E ratio is -6.40. In terms of profitability, HROWM's ROE is -0.10%, compared to POM's ROE of +0.07%. Regarding short-term risk, HROWM is less volatile compared to POM. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check POM's competition here
HROWM vs KYNB Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, KYNB has a market cap of 28.4M. Regarding current trading prices, HROWM is priced at $26.03, while KYNB trades at $7.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas KYNB's P/E ratio is -0.49. In terms of profitability, HROWM's ROE is -0.10%, compared to KYNB's ROE of -1.62%. Regarding short-term risk, HROWM is less volatile compared to KYNB. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check KYNB's competition here
HROWM vs NEUP Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, NEUP has a market cap of 27.9M. Regarding current trading prices, HROWM is priced at $26.03, while NEUP trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas NEUP's P/E ratio is -7.49. In terms of profitability, HROWM's ROE is -0.10%, compared to NEUP's ROE of -15.38%. Regarding short-term risk, HROWM is less volatile compared to NEUP. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check NEUP's competition here
HROWM vs MEDS Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, MEDS has a market cap of 13.3M. Regarding current trading prices, HROWM is priced at $26.03, while MEDS trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas MEDS's P/E ratio is -0.31. In terms of profitability, HROWM's ROE is -0.10%, compared to MEDS's ROE of -2.36%. Regarding short-term risk, HROWM is less volatile compared to MEDS. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check MEDS's competition here
HROWM vs CJJD Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, HROWM is priced at $26.03, while CJJD trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CJJD's P/E ratio is -0.46. In terms of profitability, HROWM's ROE is -0.10%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, HROWM is less volatile compared to CJJD. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check CJJD's competition here
HROWM vs MSLE Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, MSLE has a market cap of 9.2M. Regarding current trading prices, HROWM is priced at $26.03, while MSLE trades at $7.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas MSLE's P/E ratio is -4.21. In terms of profitability, HROWM's ROE is -0.10%, compared to MSLE's ROE of -0.52%. Regarding short-term risk, HROWM is less volatile compared to MSLE. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check MSLE's competition here
HROWM vs AIXC Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, AIXC has a market cap of 7.9M. Regarding current trading prices, HROWM is priced at $26.03, while AIXC trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas AIXC's P/E ratio is -0.19. In terms of profitability, HROWM's ROE is -0.10%, compared to AIXC's ROE of -1.05%. Regarding short-term risk, HROWM is less volatile compared to AIXC. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check AIXC's competition here
HROWM vs SSY Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, HROWM is priced at $26.03, while SSY trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SSY's P/E ratio is -2.86. In terms of profitability, HROWM's ROE is -0.10%, compared to SSY's ROE of -0.15%. Regarding short-term risk, HROWM is less volatile compared to SSY. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check SSY's competition here
HROWM vs HKPD Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, HKPD has a market cap of 7.3M. Regarding current trading prices, HROWM is priced at $26.03, while HKPD trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas HKPD's P/E ratio is -11.01. In terms of profitability, HROWM's ROE is -0.10%, compared to HKPD's ROE of -0.01%. Regarding short-term risk, HROWM is less volatile compared to HKPD. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check HKPD's competition here
HROWM vs MDVL Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, HROWM is priced at $26.03, while MDVL trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas MDVL's P/E ratio is -0.05. In terms of profitability, HROWM's ROE is -0.10%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, HROWM is less volatile compared to MDVL. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check MDVL's competition here
HROWM vs ATNFW Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, HROWM is priced at $26.03, while ATNFW trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ATNFW's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.10%, compared to ATNFW's ROE of -0.91%. Regarding short-term risk, HROWM is less volatile compared to ATNFW. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check ATNFW's competition here
HROWM vs BGMSP Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, HROWM is priced at $26.03, while BGMSP trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas BGMSP's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.10%, compared to BGMSP's ROE of -2.95%. Regarding short-term risk, HROWM is less volatile compared to BGMSP. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check BGMSP's competition here
HROWM vs BGMS Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, BGMS has a market cap of 2.1M. Regarding current trading prices, HROWM is priced at $26.03, while BGMS trades at $0.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas BGMS's P/E ratio is -0.15. In terms of profitability, HROWM's ROE is -0.10%, compared to BGMS's ROE of -0.58%. Regarding short-term risk, HROWM is less volatile compared to BGMS. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check BGMS's competition here
HROWM vs NVOH Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, NVOH has a market cap of 2M. Regarding current trading prices, HROWM is priced at $26.03, while NVOH trades at $22.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas NVOH's P/E ratio is 11.89. In terms of profitability, HROWM's ROE is -0.10%, compared to NVOH's ROE of +0.00%. Regarding short-term risk, HROWM is less volatile compared to NVOH. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check NVOH's competition here
HROWM vs AZNH Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, HROWM is priced at $26.03, while AZNH trades at $53.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas AZNH's P/E ratio is 38.35. In terms of profitability, HROWM's ROE is -0.10%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, HROWM is less volatile compared to AZNH. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check AZNH's competition here
HROWM vs LFLYW Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, HROWM is priced at $26.03, while LFLYW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas LFLYW's P/E ratio is -0.04. In terms of profitability, HROWM's ROE is -0.10%, compared to LFLYW's ROE of +0.17%. Regarding short-term risk, HROWM is more volatile compared to LFLYW. This indicates potentially higher risk in terms of short-term price fluctuations for HROWM.Check LFLYW's competition here
HROWM vs BIMI Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, BIMI has a market cap of 1.2K. Regarding current trading prices, HROWM is priced at $26.03, while BIMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas BIMI's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.10%, compared to BIMI's ROE of -2.94%. Regarding short-term risk, HROWM is more volatile compared to BIMI. This indicates potentially higher risk in terms of short-term price fluctuations for HROWM.Check BIMI's competition here
HROWM vs OREX Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, OREX has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03, while OREX trades at $0.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas OREX's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.10%, compared to OREX's ROE of -0.54%. Regarding short-term risk, HROWM is less volatile compared to OREX. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check OREX's competition here
HROWM vs CPD Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, CPD has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03, while CPD trades at $5.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas CPD's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.10%, compared to CPD's ROE of N/A. Regarding short-term risk, HROWM is less volatile compared to CPD. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check CPD's competition here
HROWM vs POZN Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, POZN has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03, while POZN trades at $5.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas POZN's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.10%, compared to POZN's ROE of +0.61%. Regarding short-term risk, HROWM is less volatile compared to POZN. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check POZN's competition here
HROWM vs SHPG Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03, while SHPG trades at $179.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas SHPG's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.10%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, HROWM is more volatile compared to SHPG. This indicates potentially higher risk in terms of short-term price fluctuations for HROWM.Check SHPG's competition here
HROWM vs IPXL Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03, while IPXL trades at $18.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas IPXL's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.10%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, HROWM is less volatile compared to IPXL. This indicates potentially lower risk in terms of short-term price fluctuations for HROWM.Check IPXL's competition here
HROWM vs ESRX Comparison April 2026
HROWM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HROWM stands at 1.3B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, HROWM is priced at $26.03, while ESRX trades at $92.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HROWM currently has a P/E ratio of N/A, whereas ESRX's P/E ratio is N/A. In terms of profitability, HROWM's ROE is -0.10%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, HROWM is more volatile compared to ESRX. This indicates potentially higher risk in terms of short-term price fluctuations for HROWM.Check ESRX's competition here